Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Paion AG. (8/27/15). "Press Release: Jürgen Raths, MD, Appointed as Chief Operation Officer at Paion AG". Aachen.

Organisations Organisation Paion AG
  Group Paion (Group)
  Organisation 2 Arpida AG (SWX: ARPN)
  Today Evolva Holding SA (SIX: EVE)
  Group Evolva (Group)
Products Product remimazolam (CNS 7056)
  Product 2 pharmaceutical
Persons Person Raths, Jürgen (Paion 201509–201703 COO before Executive Insight + Correvio Intl + Arpida + Lilly LEFT 3/17)
  Person 2 Spiekerkötter, Jörg (Paion 201408 Chairman of Supervisory Board before Organon Bioscience 200611–200705 CFO)

> New COO brings wealth of experience in international product launches

> Responsible for the establishment of an efficient commercial structure

PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), announces that Dr. Juergen Raths (59) has been appointed by the Supervisory Board as a new member of the Management Board of PAION AG and will be Chief Operating Officer with effect from 1 September 2015. Dr. Raths has been working for PAION as a consultant since 2014 and will be responsible for the establishment of the commercial structure to serve anesthetists in Europe and around the world.

Dr. Raths has over 25 years of experience in the European and global pharma business, with positions held in medical sales and marketing as well as general management in Europe and the U.S He was Associate Partner with Executive Insight, a Zurich-based pharma consultancy firm, focusing on biotech, pharma and medical device companies. Dr. Raths focused on supporting Pharma companies entering the European market. He formerly served as President and CEO of private specialty pharmaceutical company Correvio International in Geneva as well as President and CEO of publicly traded Arpida AG based in Basel. Dr. Raths spent 18 years with Eli Lilly and Company in various senior executive roles including Head Critical Care Europe, and he spent three years at Corporate Headquarters in Indianapolis in Health Economics and New Product Planning. He holds an MD from the University of Bonn. Dr. Raths brings to PAION exceptional leadership experience in company formation, change management and global business development.

Dr. Jörg Spiekerkötter, Chairman of the Supervisory Board of PAION AG, explained why Dr. Raths was the candidate of choice: “Our decision to appoint Dr. Raths as COO aligns with our strategy to broaden the know-how of the executive management of PAION for the future and to transform PAION into a commercial-stage company. We are bringing on board an experienced business executive with a strong background in global product launches. I wish him every success in his new function."

"I have known Jürgen for many years and with his deep experience in building up commercial structures he was our favorite candidate. Juergen will support the company on its path through Phase III development, approval and commercialization of Remimazolam", commented Dr. Wolfgang Söhngen,



PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany, with further sites in Cambridge, UK, and New Jersey, U.S. The company has a track record of developing hospital-based treatments for which there is substantial unmet medical need. PAION’s strategy is to participate in the commercialization of Remimazolam and extend its business with a focus on anesthesia/critical care products. Remimazolam is the building block for its future marketing activities.

For more information please visit

PAION Contact
Ralf Penner
Director Investor Relations / Public Relations
Martinstrasse 10-12
52062 Aachen – Germany
Phone: +49 241 4453-152


This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG’s management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.

Record changed: 2017-04-02


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Paion (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top